Cetera Investment Advisers Purchases 8,524 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Cetera Investment Advisers raised its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 13.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 72,681 shares of the medical research company's stock after purchasing an additional 8,524 shares during the period. Cetera Investment Advisers' holdings in IQVIA were worth $12,814,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in IQV. American National Bank & Trust purchased a new stake in shares of IQVIA in the first quarter valued at about $26,000. Golden State Wealth Management LLC boosted its holdings in IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after purchasing an additional 130 shares in the last quarter. AllSquare Wealth Management LLC acquired a new position in IQVIA during the 1st quarter worth approximately $33,000. ST Germain D J Co. Inc. boosted its stake in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after buying an additional 76 shares in the last quarter. Finally, GKV Capital Management Co. Inc. acquired a new position in IQVIA during the fourth quarter worth $39,000. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Stock Down 1.8%

Shares of NYSE:IQV traded down $3.42 during trading on Friday, hitting $182.44. 1,644,130 shares of the company's stock traded hands, compared to its average volume of 2,321,248. The company has a 50-day moving average price of $162.11 and a 200-day moving average price of $170.07. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. The company has a market cap of $31.01 billion, a price-to-earnings ratio of 26.40, a price-to-earnings-growth ratio of 2.04 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same quarter last year, the firm posted $2.64 EPS. The company's quarterly revenue was up 5.3% on a year-over-year basis. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. The trade was a 15.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

IQV has been the subject of a number of research reports. Hsbc Global Res downgraded shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Cowen reissued a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. William Blair reaffirmed an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Citigroup reissued a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Finally, HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and cut their target price for the stock from $260.00 to $160.00 in a research report on Friday, April 25th. Seven analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, IQVIA presently has a consensus rating of "Moderate Buy" and an average price target of $228.62.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.